The anti-cancer drug, CVM-1118, has received approval from China’s National Medical Products Administration (NMPA) to initiate a Phase II clinical trial in China under Protocol No. CVM-010.

The Phase II trial will evaluate the safety and efficacy of CVM-1118 in combination with Tyvyt® (sintilimab injection), an immunotherapy product supplied by Innovent Biologics, Inc., and transarterial chemoembolization (TACE) in patients with unresectable intermediate-stage hepatocellular carcinoma (HCC) without extrahepatic metastasis.